125 related articles for article (PubMed ID: 27391157)
1. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.
Alver TN; Lavelle TJ; Longva AS; Øy GF; Hovig E; Bøe SL
Oncotarget; 2016 Aug; 7(34):55128-55140. PubMed ID: 27391157
[TBL] [Abstract][Full Text] [Related]
2. Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway.
Alver TN; Heintz KM; Hovig E; Bøe SL
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1736. PubMed ID: 36251678
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.
Capparelli C; Rosenbaum S; Berger AC; Aplin AE
J Biol Chem; 2015 Oct; 290(40):24267-77. PubMed ID: 26269601
[TBL] [Abstract][Full Text] [Related]
4. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
5. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.
Han S; Ren Y; He W; Liu H; Zhi Z; Zhu X; Yang T; Rong Y; Ma B; Purwin TJ; Ouyang Z; Li C; Wang X; Wang X; Yang H; Zheng Y; Aplin AE; Liu J; Shao Y
Nat Commun; 2018 Jan; 9(1):28. PubMed ID: 29295999
[TBL] [Abstract][Full Text] [Related]
6. MITF Modulates Therapeutic Resistance through EGFR Signaling.
Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
[TBL] [Abstract][Full Text] [Related]
7. NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.
Buac K; Xu M; Cronin J; Weeraratna AT; Hewitt SM; Pavan WJ
Pigment Cell Melanoma Res; 2009 Dec; 22(6):773-84. PubMed ID: 19659570
[TBL] [Abstract][Full Text] [Related]
8. Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling).
Meng D; Pan H; Chen Y; Ding J; Dai Y
Obes Res Clin Pract; 2021; 15(2):145-151. PubMed ID: 33541789
[TBL] [Abstract][Full Text] [Related]
9. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
10. Reliability of immunostaining using pan-melanoma cocktail, SOX10, and microphthalmia transcription factor in confirming a diagnosis of melanoma on fine-needle aspiration smears.
Clevenger J; Joseph C; Dawlett M; Guo M; Gong Y
Cancer Cytopathol; 2014 Oct; 122(10):779-85. PubMed ID: 24954720
[TBL] [Abstract][Full Text] [Related]
11. Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.
Poindexter KM; Matthew S; Aronchik I; Firestone GL
Cell Biol Toxicol; 2016 Apr; 32(2):103-19. PubMed ID: 27055402
[TBL] [Abstract][Full Text] [Related]
12. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1.
Cao Z; Wu X; Yen L; Sweeney C; Carraway KL
Mol Cell Biol; 2007 Mar; 27(6):2180-8. PubMed ID: 17210635
[TBL] [Abstract][Full Text] [Related]
13. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
[TBL] [Abstract][Full Text] [Related]
14. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.
Ieguchi K; Fujita M; Ma Z; Davari P; Taniguchi Y; Sekiguchi K; Wang B; Takada YK; Takada Y
J Biol Chem; 2010 Oct; 285(41):31388-98. PubMed ID: 20682778
[TBL] [Abstract][Full Text] [Related]
15. Frequent mutations in the MITF pathway in melanoma.
Cronin JC; Wunderlich J; Loftus SK; Prickett TD; Wei X; Ridd K; Vemula S; Burrell AS; Agrawal NS; Lin JC; Banister CE; Buckhaults P; Rosenberg SA; Bastian BC; Pavan WJ; Samuels Y
Pigment Cell Melanoma Res; 2009 Aug; 22(4):435-44. PubMed ID: 19422606
[TBL] [Abstract][Full Text] [Related]
16. FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.
Wang J; Li L; Liu S; Zhao Y; Wang L; Du G
Oncotarget; 2016 Dec; 7(51):84375-84387. PubMed ID: 27533251
[TBL] [Abstract][Full Text] [Related]
17. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.
Pucciarelli D; Lengger N; Takáčová M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Mol Med Rep; 2016 Apr; 13(4):3281-8. PubMed ID: 26936534
[TBL] [Abstract][Full Text] [Related]
19. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
20. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.
Capparelli C; Rosenbaum S; Berman-Booty LD; Salhi A; Gaborit N; Zhan T; Chervoneva I; Roszik J; Woodman SE; Davies MA; Setiady YY; Osman I; Yarden Y; Aplin AE
Cancer Res; 2015 Sep; 75(17):3554-67. PubMed ID: 26206558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
